Ignite Creation Date:
2024-05-06 @ 5:14 PM
Last Modification Date:
2024-10-26 @ 2:25 PM
Study NCT ID:
NCT05241093
Status:
RECRUITING
Last Update Posted:
2024-05-14
First Post:
2022-01-16
Brief Title:
A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia AML
Sponsor:
Tarapeutics Science Inc
Organization:
Tarapeutics Science Inc
Organization Data
Organization:
Tarapeutics Science Inc
Class:
INDUSTRY
Study ID:
HYML-122-03
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Tarapeutics Science Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None